scholarly journals Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review

2021 ◽  
Author(s):  
Ying Zheng ◽  
Helene Vioix ◽  
Frank X Liu ◽  
Barinder Singh ◽  
Sakshi Sharma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Single Gene ◽  
Economic Value ◽  
Cost Effective ◽  
Small Cell ◽  
Small Cell Lung ◽  
Gene Testing ◽  
Biomarker Testing

We aimed to assess the diagnostic and economic value of next-generation sequencing (NGS) versus single-gene testing, and of liquid biopsy (LBx) versus tissue biopsy (TBx) in non-small-cell lung cancer biomarker testing through literature review. Embase and MEDLINE were searched to identify relevant studies (n = 43) from 2015 to 2020 in adults with advanced non-small-cell lung cancer. For NGS versus single-gene testing, concordance was 70–99% and sensitivity was 86–100%. For LBx versus TBx, specificity was 43–100% and sensitivity was ≥60%. Turnaround times were longer for NGS versus single-gene testing (but not vs sequential testing) and faster for LBx versus TBx. NGS was cost-effective, and LBx reduced US per-patient costs. NGS versus single-gene testing and LBx versus TBx were concordant. NGS and LBx may be cost-effective for initial screening.

scholarly journals Tumor biomarker testing in non-small-cell lung cancer: A decade of change

Lung Cancer ◽  
2018 ◽  
Vol 116 ◽  
pp. 90-95 ◽  
Author(s):  
Paul A. VanderLaan ◽  
Deepa Rangachari ◽  
Adnan Majid ◽  
Mihir S. Parikh ◽  
Sidharta P. Gangadharan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Tumor Biomarker ◽  
Small Cell Lung ◽  
Biomarker Testing

scholarly journals Updates Regarding Biomarker Testing for Non–Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable

2019 ◽  
Vol 14 (3) ◽  
pp. 338-342 ◽  
Author(s):  
Edward S. Kim ◽  
Upal Basu Roy ◽  
Jennifer L. Ersek ◽  
Jennifer King ◽  
Robert A. Smith ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Biomarker Testing

Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non–small-cell Lung Cancer

2020 ◽  
Vol 21 (6) ◽  
pp. 477-481
Author(s):  
Apostolia M. Tsimberidou ◽  
Sheryl Elkin ◽  
Robert Dumanois ◽  
Daryl Pritchard
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Economic Value ◽  
Small Cell ◽  
Personalized Therapy ◽  
Small Cell Lung ◽  
Genetic Sequencing

Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 6595-6595
Author(s):  
Charles Henry Lim ◽  
Lisa Le ◽  
Frances A. Shepherd ◽  
Ronald Feld ◽  
Ronald L. Burkes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Decision ◽  
Small Cell ◽  
Small Cell Lung ◽  
Time To Treatment ◽  
Biomarker Testing

A novel mutation panel for predicting etoposide in small cell lung cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20090-e20090
Author(s):  
Peng Luo ◽  
Zhengang Qiu ◽  
Anqi Lin ◽  
Kun Li ◽  
Weiyin Lin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Drug Sensitivity ◽  
Novel Mutation ◽  
Single Gene ◽  
Small Cell ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy

e20090 Background: Platinum-based chemotherapy, consisting of etoposide and cisplatin (EP), has been the cornerstone of therapy for extensive-stage small cell lung cancer (ES-SCLC) for decades. Despite the marked initial sensitivity of SCLC to chemotherapy, EP regimens cannot avoid the emergence of drug resistance in clinical practice. With the rise of new chemotherapy regimens in recent years and the primary resistance or insensitivity of ES-SCLC to EP regimens, it is desirable to be able to identify patients with resistant or insensitive ES-SCLC. Methods: The sequencing and drug sensitivity data of SCLC cell lines were provided by The Genomics of Drug Sensitivity in Cancer Project (GDSC); the data regarding of sensitivity to etoposide of 54 SCLC cell lines were analyzed, and etoposide-sensitive cell lines and etoposide-resistant cell lines were differentiated according to the IC50 values defined by the GDSC. ROC curve analysis was performed on all mutations and combinations of mutations to select the optimal panel to predict resistance to etoposide. Results: Receiver Operating Characteristic(ROC) analysis of etoposide resistance revealed that the most significant single gene mutation indicating resistance to etoposide was CSMD3, and the accuracy of predicting resistance to etoposide proved to be the highest when there was any mutation in CSMD3/PCLO/RYR1/EPB41L3, area under the curve (AUC) = 0.804 (95% confidence interval (CI): 0.679-0.930, p < 0.001). Conclusions: This study found that a panel with four genes (CSMD3, EPB41L3, PCLO, and RYR1) can accurately predict sensitivity to etoposide. These findings provide new insights into the overall treatment for patients with ES-SCLC that is resistant or insensitive to etoposide.

Sign in / Sign up

Export Citation Format

Share Document